Journey Medical Corporation (DERM)
| Market Cap | 97.14M |
| Revenue (ttm) | 57.77M |
| Net Income (ttm) | -18.34M |
| Shares Out | 20.89M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,617 |
| Open | 4.750 |
| Previous Close | 4.710 |
| Day's Range | 4.552 - 4.830 |
| 52-Week Range | 2.850 - 8.100 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+104.3%) |
| Earnings Date | Nov 12, 2024 |
About DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topi... [Read more]
Financial Performance
In 2023, Journey Medical's revenue was $79.18 million, an increase of 7.48% compared to the previous year's $73.67 million. Losses were -$3.85 million, -87.00% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 104.30% from the latest price.
News
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T.
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subject...
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses o...
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Foun...
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from...
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide ...
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and mar...
Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on...
Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founde...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% in...
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on...
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript
Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024 Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling an...
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Provides additional capital for general corporate purposes including funding to s...
The Strategic Evolution Of Journey Medical In Dermatological Care
Journey Medical shows a meteoric rise, led by strategic focus on dermatology and product innovation. Despite challenges, DFD-29, an oral treatment for rosacea, shows promise, potentially revolutionizi...